The fallout from the F.D.A.’s rejection of a new treatment for PTSD worries researchers and experts who fear other psychedelic drugs in the pipeline could be jeopardized.
Category: Lykos Therapeutics
-
Three MDMA Studies Are Retracted by Scientific Journal
The psychedelic treatment, for PTSD, was rejected last week by government regulators.
-
F.D.A. Declines to Approve MDMA Therapy, Seeking More Study
The agency said there was insufficient data to allow the use of a treatment for PTSD that involves the drug known as Ecstasy, according to the company seeking approval.
-
Veterans and Lawmakers Lobby for Approval of MDMA Therapy
The F.D.A. is poised to rule on the therapeutic use of the club drug Ecstasy, a potential watershed moment in the nascent field of psychedelic medicine.
-
FDA Panel Rejects Use of MDMA for Treatment of PTSD
An independent group of experts expressed concerns that the data from clinical trials did not outweigh risks for treatment of post-traumatic stress disorder.
-
FDA Panel Weights MDMA Therapy for PTSD
An independent group of experts is meeting Tuesday to consider whether to allow use of this illegal drug, also known as Ecstasy, to treat PTSD.